Product Name: Eliquis 2.5mg Film-Coated Tablets
Registration Number (Malaysia): MAL13085062ARZ
Manufacturer: Pfizer Ireland Pharmaceuticals
Marketing Authorisation Holder: Pfizer (Malaysia) Sdn. Bhd.
Importer: Pfizer (Malaysia) Sdn. Bhd.
Distributor: Zuellig Pharma
Apixaban – 2.5 mg
Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
Administration: Take orally with or without food.
Dosage:
Prevention of VTE (hip or knee replacement surgery): 2.5 mg twice daily.
Prevention of stroke and systemic embolism in NVAF: 5 mg twice daily; dose may be reduced to 2.5 mg twice daily in patients with at least two of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
Treatment of DVT and PE: 10 mg twice daily for the first 7 days, followed by 5 mg twice daily.
Prevention of recurrent DVT and PE: 2.5 mg twice daily following 6 months of treatment with apixaban 5 mg twice daily or another anticoagulant .
Precautions: Swallow the tablet whole; do not chew, crush, or break. If you have difficulty swallowing, the tablet may be crushed and suspended in water, apple juice, or mixed with apple puree. Consume the mixture immediately or within 4 hours
Malaysia
